STOCK TITAN

[Form 4] HEICO CORP CL A Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing overview: Abbott Laboratories (ABT) Executive Vice President Louis H. Morrone reported one transaction dated 30 June 2025.

  • Transaction code: F (as reported in the form).
  • Shares affected: 269 common shares without par value.
  • Transaction price: $134.38 per share.
  • Post-transaction direct holdings: 66,609 common shares.
  • Indirect holdings: 12 common shares held in the Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) as of 30 June 2025.

There were no derivative security transactions reported and no indication of additional purchases, option exercises, or sales beyond the single Code F entry. Morrone remains an insider with substantial equity exposure to Abbott Laboratories after the reported withholding.

Panoramica della dichiarazione Form 4: Louis H. Morrone, Vicepresidente Esecutivo di Abbott Laboratories (ABT), ha riportato una transazione datata 30 giugno 2025.

  • Codice della transazione: F (come indicato nel modulo).
  • Azioni coinvolte: 269 azioni ordinarie senza valore nominale.
  • Prezzo della transazione: 134,38 $ per azione.
  • Detenzioni dirette dopo la transazione: 66.609 azioni ordinarie.
  • Detenzioni indirette: 12 azioni ordinarie detenute nel Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) al 30 giugno 2025.

Non sono state segnalate transazioni su titoli derivati né indicazioni di acquisti aggiuntivi, esercizi di opzioni o vendite oltre l'unica voce con codice F. Morrone rimane un soggetto interno con una significativa esposizione azionaria in Abbott Laboratories dopo la trattenuta segnalata.

Resumen de la presentación del Formulario 4: Louis H. Morrone, Vicepresidente Ejecutivo de Abbott Laboratories (ABT), reportó una transacción fechada el 30 de junio de 2025.

  • Código de transacción: F (según se indica en el formulario).
  • Acciones afectadas: 269 acciones comunes sin valor nominal.
  • Precio de la transacción: 134,38 $ por acción.
  • Participaciones directas después de la transacción: 66.609 acciones comunes.
  • Participaciones indirectas: 12 acciones comunes mantenidas en el Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) al 30 de junio de 2025.

No se reportaron transacciones con valores derivados ni indicios de compras adicionales, ejercicios de opciones o ventas más allá de la única entrada con código F. Morrone sigue siendo un insider con una exposición significativa en acciones de Abbott Laboratories tras la retención reportada.

양식 4 제출 개요: Abbott Laboratories(ABT) 부사장 Louis H. Morrone가 2025년 6월 30일자 거래 하나를 보고했습니다.

  • 거래 코드: F (양식에 보고된 대로).
  • 영향을 받은 주식 수: 액면가 없는 보통주 269주.
  • 거래 가격: 주당 $134.38.
  • 거래 후 직접 보유 주식: 보통주 66,609주.
  • 간접 보유 주식: 2025년 6월 30일 기준 Abbott Laboratories Stock Retirement Trust(Profit Sharing Trust)에 보유 중인 보통주 12주.

파생 증권 거래는 보고되지 않았으며, 추가 매수, 옵션 행사 또는 판매에 대한 다른 기록은 코드 F 단일 항목 외에 없습니다. Morrone는 보고된 원천징수 후에도 Abbott Laboratories에 상당한 지분 노출을 가진 내부자입니다.

Vue d'ensemble du dépôt du formulaire 4 : Louis H. Morrone, vice-président exécutif d'Abbott Laboratories (ABT), a déclaré une transaction datée du 30 juin 2025.

  • Code de transaction : F (tel que rapporté dans le formulaire).
  • Actions concernées : 269 actions ordinaires sans valeur nominale.
  • Prix de la transaction : 134,38 $ par action.
  • Détentions directes après la transaction : 66 609 actions ordinaires.
  • Détentions indirectes : 12 actions ordinaires détenues dans le Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) au 30 juin 2025.

Aucune transaction sur titres dérivés n'a été signalée, ni indication d'achats supplémentaires, d'exercices d'options ou de ventes au-delà de la seule entrée avec le code F. Morrone reste un initié avec une exposition importante au capital d'Abbott Laboratories après la retenue déclarée.

Übersicht der Form 4-Meldung: Louis H. Morrone, Executive Vice President von Abbott Laboratories (ABT), meldete eine Transaktion vom 30. Juni 2025.

  • Transaktionscode: F (wie im Formular angegeben).
  • Betroffene Aktien: 269 Stammaktien ohne Nennwert.
  • Transaktionspreis: 134,38 $ pro Aktie.
  • Direktbestand nach der Transaktion: 66.609 Stammaktien.
  • Indirekte Bestände: 12 Stammaktien, gehalten im Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) zum 30. Juni 2025.

Es wurden keine Derivatgeschäfte gemeldet und keine Hinweise auf weitere Käufe, Ausübung von Optionen oder Verkäufe über den einzelnen Eintrag mit Code F hinaus. Morrone bleibt ein Insider mit erheblicher Aktienbeteiligung an Abbott Laboratories nach der gemeldeten Einbehaltung.

Positive
  • None.
Negative
  • None.

Insights

TL;DR — Minor insider share disposition; immaterial to ABT valuation.

The Form 4 shows Executive Vice President Louis H. Morrone had 269 shares withheld/disposed at $134.38 on 30 June 2025, leaving 66,609 directly held shares plus 12 indirect shares. The volume represents a fraction of his ownership and an immaterial percentage of Abbott’s total shares outstanding. No derivative activity or multiple insiders were involved. Given the small size and lack of market-moving context, the filing is neutral for investors.

Panoramica della dichiarazione Form 4: Louis H. Morrone, Vicepresidente Esecutivo di Abbott Laboratories (ABT), ha riportato una transazione datata 30 giugno 2025.

  • Codice della transazione: F (come indicato nel modulo).
  • Azioni coinvolte: 269 azioni ordinarie senza valore nominale.
  • Prezzo della transazione: 134,38 $ per azione.
  • Detenzioni dirette dopo la transazione: 66.609 azioni ordinarie.
  • Detenzioni indirette: 12 azioni ordinarie detenute nel Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) al 30 giugno 2025.

Non sono state segnalate transazioni su titoli derivati né indicazioni di acquisti aggiuntivi, esercizi di opzioni o vendite oltre l'unica voce con codice F. Morrone rimane un soggetto interno con una significativa esposizione azionaria in Abbott Laboratories dopo la trattenuta segnalata.

Resumen de la presentación del Formulario 4: Louis H. Morrone, Vicepresidente Ejecutivo de Abbott Laboratories (ABT), reportó una transacción fechada el 30 de junio de 2025.

  • Código de transacción: F (según se indica en el formulario).
  • Acciones afectadas: 269 acciones comunes sin valor nominal.
  • Precio de la transacción: 134,38 $ por acción.
  • Participaciones directas después de la transacción: 66.609 acciones comunes.
  • Participaciones indirectas: 12 acciones comunes mantenidas en el Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) al 30 de junio de 2025.

No se reportaron transacciones con valores derivados ni indicios de compras adicionales, ejercicios de opciones o ventas más allá de la única entrada con código F. Morrone sigue siendo un insider con una exposición significativa en acciones de Abbott Laboratories tras la retención reportada.

양식 4 제출 개요: Abbott Laboratories(ABT) 부사장 Louis H. Morrone가 2025년 6월 30일자 거래 하나를 보고했습니다.

  • 거래 코드: F (양식에 보고된 대로).
  • 영향을 받은 주식 수: 액면가 없는 보통주 269주.
  • 거래 가격: 주당 $134.38.
  • 거래 후 직접 보유 주식: 보통주 66,609주.
  • 간접 보유 주식: 2025년 6월 30일 기준 Abbott Laboratories Stock Retirement Trust(Profit Sharing Trust)에 보유 중인 보통주 12주.

파생 증권 거래는 보고되지 않았으며, 추가 매수, 옵션 행사 또는 판매에 대한 다른 기록은 코드 F 단일 항목 외에 없습니다. Morrone는 보고된 원천징수 후에도 Abbott Laboratories에 상당한 지분 노출을 가진 내부자입니다.

Vue d'ensemble du dépôt du formulaire 4 : Louis H. Morrone, vice-président exécutif d'Abbott Laboratories (ABT), a déclaré une transaction datée du 30 juin 2025.

  • Code de transaction : F (tel que rapporté dans le formulaire).
  • Actions concernées : 269 actions ordinaires sans valeur nominale.
  • Prix de la transaction : 134,38 $ par action.
  • Détentions directes après la transaction : 66 609 actions ordinaires.
  • Détentions indirectes : 12 actions ordinaires détenues dans le Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) au 30 juin 2025.

Aucune transaction sur titres dérivés n'a été signalée, ni indication d'achats supplémentaires, d'exercices d'options ou de ventes au-delà de la seule entrée avec le code F. Morrone reste un initié avec une exposition importante au capital d'Abbott Laboratories après la retenue déclarée.

Übersicht der Form 4-Meldung: Louis H. Morrone, Executive Vice President von Abbott Laboratories (ABT), meldete eine Transaktion vom 30. Juni 2025.

  • Transaktionscode: F (wie im Formular angegeben).
  • Betroffene Aktien: 269 Stammaktien ohne Nennwert.
  • Transaktionspreis: 134,38 $ pro Aktie.
  • Direktbestand nach der Transaktion: 66.609 Stammaktien.
  • Indirekte Bestände: 12 Stammaktien, gehalten im Abbott Laboratories Stock Retirement Trust (Profit Sharing Trust) zum 30. Juni 2025.

Es wurden keine Derivatgeschäfte gemeldet und keine Hinweise auf weitere Käufe, Ausübung von Optionen oder Verkäufe über den einzelnen Eintrag mit Code F hinaus. Morrone bleibt ein Insider mit erheblicher Aktienbeteiligung an Abbott Laboratories nach der gemeldeten Einbehaltung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MENDELSON VICTOR H

(Last) (First) (Middle)
825 BRICKELL BAY DRIVE, SUITE 1644

(Street)
MIAMI FL 33131

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HEICO CORP [ HEI, HEI.A ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) X Other (specify below)
Co-CEO Member of 10% owner group
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1,234,950 D
Class A Common Stock 06/23/2025 G 1,440 D $0 221,082 D
Class A Common Stock 06/30/2025 G 3,187 D $0 217,895 D
Class A Common Stock 191,440 I Owned by Corporation(1)
Common Stock 172,515 I Owned by Partnership(2)
Common Stock 4,762 I As custodian for children
Class A Common Stock 19,136 I As custodian for children
Common Stock 93,097 I By 401(k)(3)
Class A Common Stock 88,323 I By 401(k)(3)
Common Stock 921 I By Keogh Account
Class A Common Stock 16,133 I By Keogh Account
Common Stock 568,140 I By Trusts(4)
Class A Common Stock 137,199 I By Trusts(4)
Common Stock 28,806 I By Trusts(5)
Class A Common Stock 8,465 I By Trusts(5)
Common Stock 4,072 I By 409A Plan(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares owned by Mendelson International Corporation whose stock is owned solely by the Reporting Person and Eric Mendelson, the brother of the Reporting Person.
2. Represents shares owned by VHM Management Limited Partners, a partnership whose sole general partner is a corporation controlled by the Reporting Person.
3. Represents shares held for the benefit of the Reporting Person by the HEICO Corporation 401(k), based on a plan statement dated June 27, 2025.
4. Represents shares gifted by the Reporting Person to trusts for the benefit of the Reporting Person's immediate family members and whose Trustee is the Reporting Person.
5. Represents shares owned by the Victor H. Mendelson Revocable Investment Trust which is owned solely by the Reporting Person.
6. Represents shares held for the reporting person by the HEICO Corporation Leadership Compensation Plan (409A Plan).
Remarks:
/s/ Victor H. Mendelson 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Heico Corp

NYSE:HEI

HEI Rankings

HEI Latest News

HEI Stock Data

44.06B
117.27M
23.03%
73.22%
1.52%
Aerospace & Defense
Aircraft Engines & Engine Parts
Link
United States
HOLLYWOOD